Pulmonology: TMCx Spring 2020 Clinical Focus

Respiratory diseases are one of the leading causes of death around the world. TMC institutions are some of the highest ranked in pulmonary care for pediatrics and adults; leading the treatment of chronic and acute conditions such as COPD, asthma, pulmonary hypertension, and respiratory infections. There’s no better place than the TMC to scale your technology and solve these issues in pulmonology. TMCx has previously worked with companies such as Aidar Health and Strados Labs, and we are looking for companies that are leading the charge to better treat patients with respiratory conditions. Apply by Dec 13th.

TMCx welcomes applications for its revamped theme-oriented healthcare accelerator program! Serving more than 60 institutions, including 23 hospitals, TMCx provides pathways for meaningful engagements between healthcare startups and their customers, users, and other key stakeholders. We define successful engagements to include pilots, pre-clinical validation, clinical trials, or sales contracts with our member institutions. We have restructured the TMCx program around these engagement milestones. If you are an early-stage medical device or digital health company seeking these types of engagements with clinical and academic partners, this program is for you!

To apply to our next TMCx accelerator, visit us at tmc.edu/innovation/apply/.